Can a Blood Test Predict Immunotherapy Response? What Proof Is Still Needed

What is being tested, and why

Immunotherapy helps some people a great deal and does nothing for others. Predicting which is which, before treatment starts, would spare people months of side effects that were never going to pay off.

So researchers are studying whether material in blood can describe the immune situation around a tumor. These approaches may combine tumor DNA, proteins, immune signals, and computer models into a single score.

This page explains federal sources. It is not medical advice and does not suggest a test or treatment.

What NCI says a tumor marker can do

NCI defines a tumor marker as anything present in or produced by cancer cells, or by other cells responding to cancer or to certain noncancerous conditions, that gives information about a cancer.

The list of jobs a marker can do is longer than most people expect. It can help with diagnosis. It can indicate the type or stage. It can inform an estimate of prognosis. It can suggest what treatment may be effective. It can show how well treatment is working, through repeated measurements over time. And it can be used to check for recurrence after treatment ends.

NCI also notes that tumors shed cells and material into blood, and that these can be measured by tests called liquid biopsies.

But NCI attaches a condition throughout. A marker is useful when studies show the test is reliable and its result can guide a decision that matters. Our page on tumor markers goes through what they do and do not settle.

How immunotherapy targets are chosen now

It helps to know what is already in use. NCI explains that immune checkpoints are a normal part of the immune system, there to keep an immune response from destroying healthy cells.

Checkpoint proteins such as PD-L1 on tumor cells and PD-1 on T cells bind together and send an "off" signal to the T cell. Some tumors turn the T cell response down by producing a lot of PD-L1. Checkpoint inhibitor drugs block that binding so the off signal is not sent, which lets T cells attack cancer cells. Other drugs act against a checkpoint protein called CTLA-4.

NCI's guidance on biomarker testing makes the general rule explicit: some treatments, including immunotherapies, may only work for people whose cancers carry certain biomarkers. A new blood test would have to earn a place next to the tests already doing that job.

Association is not a decision rule

A blood marker can be linked with response without being ready to choose anyone's treatment. The real test is whether using it produces better decisions than current methods.

Several details determine that, and good coverage names them:

• When was the blood drawn, relative to treatment?
• What exactly did the test measure?
• How was the cutoff for a positive result chosen, and was it fixed in advance?
• Did the finding hold up in a separate group of people?

There is a trap in the last one. A marker that tracks how much cancer is present will fall when treatment works. That looks impressive in hindsight and still tells you nothing in advance about which treatment to pick.

What would make it ready

The strongest study sets the rule before it is used, then tests it in a separate population receiving defined care. It reports sensitivity and specificity, and it reports what happened to people in each decision group.

After that, a randomized trial may still be needed. That trial asks the only question that matters in the clinic: does treatment guided by the test lead to more benefit, or less avoidable harm, than treatment chosen the usual way?

Where this stops short

• A research blood test is not automatically available in routine care.
• Predicting response is not the same as guaranteeing response.
• A test may behave differently across cancer types and across immunotherapy drugs.
• Side effects remain unpredictable. NCI notes that doctors and nurses cannot know for sure when or if checkpoint inhibitor side effects will occur, or how serious they will be.

The full clinical picture, alongside approved biomarker tests, is still what immunotherapy decisions rest on. And no blood score replaces the diagnostic workup that established the cancer in the first place.

Questions about a predictive blood test

• Was the test validated in a separate group of patients?
• Did using the result actually improve decisions or outcomes?
• Is this test approved or recommended for this cancer?
• What happens if the blood result and the tumor testing disagree?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.